애로우헤드 파마슈티컬스, Inc.
MX ˙ BMV ˙ US04280A1007
SecurityMX:ARWR / Arrowhead Pharmaceuticals, Inc.
InstitutionUs Bancorp \de\
Latest Disclosed Ownership34,683 shares
Latest Disclosed Value $ 2,174,625
Us Bancorp \de\ reports 0.41% increase in ownership of ARWR / Arrowhead Pharmaceuticals, Inc.

On May 14, 2026 - Us Bancorp \de\ filed a 13F-HR form disclosing ownership of 34,683 shares of Arrowhead Pharmaceuticals, Inc. (MX:ARWR) valued at $2,174,625 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 30, 2026 disclosing 34,543 shares of Arrowhead Pharmaceuticals, Inc.. This represents a change in shares of 0.41% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 34,683 140 0.41 2,175 -5.19 0.0008
2026-01-30 2025-12-31 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 34,543 151 0.44 2,293 93.34 0.0027
2025-11-12 2025-09-30 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 34,392 -11 -0.03 1,186 118.42 0.0014
2025-07-24 2025-06-30 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 34,403 1,302 3.93 544 28.98 0.0007
2025-05-08 2025-03-31 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 33,101 -1,421 -4.12 422 -35.13 0.0006
2025-02-05 2024-12-31 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 34,522 -5,601 -13.96 649 -16.47 0.0008
2024-10-28 2024-09-30 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 40,123 -4,987 -11.06 777 -33.70 0.0010
2024-08-07 2024-06-30 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 45,110 1,314 3.00 1,172 -6.39 0.0016
2024-05-08 2024-03-31 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 43,796 -2,409 -5.21 1,253 -11.39 0.0017
2024-02-09 2023-12-31 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 46,205 -949 -2.01 1,414 11.52 0.0021
2023-11-03 2023-09-30 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 47,154 1,220 2.66 1,267 -22.65 0.0021
2023-08-10 2023-06-30 13F ARROWHEAD PHARMACEUTICALS IN COM 04280A100 45,934 3,191 7.47 1,638 50.97 0.0026
2023-05-09 2023-03-31 13F ARROWHEAD PHARMACEUTICALS COMMON STOCK 04280A100 42,743 24,781 137.96 1,086 49.04 0.0018
2023-02-13 2022-12-31 13F ARROWHEAD PHARMACEUTICALS COMMON STOCK 04280A100 17,962 -4,400 -19.68 729 -1.62 0.0013
2022-10-27 2022-09-30 13F ARROWHEAD PHARMACEUTICALS COMMON STOCK 04280A100 22,362 6,292 39.15 740 30.74 0.0015
2022-08-01 2022-06-30 13F ARROWHEAD PHARMACEUTICALS COMMON STOCK 04280A100 16,070 -1,348 -7.74 566 -29.34 0.0011
2022-05-11 2022-03-31 13F ARROWHEAD PHARMACEUTICALS COMMON STOCK 04280A100 17,418 1,069 6.54 801 -25.97 0.0013
2022-02-11 2021-12-31 13F ARROWHEAD PHARMACEUTICALS COMMON STOCK 04280A100 16,349 1,590 10.77 1,082 17.35 0.0017
2021-11-10 2021-09-30 13F ARROWHEAD PHARMACEUTICALS COMMON STOCK 04280A100 14,759 1,140 8.37 922 -18.26 0.0017
2021-08-05 2021-06-30 13F ARROWHEAD PHARMACEUTICALS COMMON STOCK 04280A100 13,619 1,024 8.13 1,128 34.93 0.0021
2021-04-28 2021-03-31 13F ARROWHEAD PHARMACEUTICALS COMMON STOCK 04280A100 12,595 8,087 179.39 836 141.62 0.0017
2021-02-04 2020-12-31 13F ARROWHEAD PHARMACEUTICALS COMMON STOCK 04280A100 4,508 54 1.21 346 81.15 0.0007
2020-11-10 2020-09-30 13F ARROWHEAD PHARMACEUTICALS COMMON STOCK 04280A100 4,454 -207 -4.44 191 -4.98 0.0005
2020-08-07 2020-06-30 13F ARROWHEAD PHARMACEUTICALS COMMON STOCK 04280A100 4,661 -180 -3.72 201 44.60 0.0005
2020-05-13 2020-03-31 13F ARROWHEAD PHARMACEUTICALS COMMON STOCK 04280A100 4,841 -267 -5.23 139 -57.10 0.0004
2020-02-04 2019-12-31 13F ARROWHEAD PHARMACEUTICALS COMMON STOCK 04280A100 5,108 278 5.76 324 138.24 0.0008
2019-11-08 2019-09-30 13F ARROWHEAD PHARMACEUTICALS COMMON STOCK 04280A100 4,830 222 4.82 136 10.57 0.0004
2019-08-13 2019-06-30 13F ARROWHEAD PHARMACEUTICALS COMMON STOCK 04280A100 4,608 122 2.72 123 50.00 0.0003
2019-05-08 2019-03-31 13F ARROWHEAD PHARMACEUTICALS COMMON STOCK 04280A100 4,486 -265 -5.58 82 38.98 0.0002
2019-02-13 2018-12-31 13F ARROWHEAD PHARMACEUTICALS COMMON STOCK 04280A100 4,751 4,751 59 0.0002
2017-02-08 2016-12-31 13F ARROWHEAD PHARMACEUTICALS COMMON STOCK 04280A100 0 -1,000 -100.00 0 -100.00
2016-11-04 2016-09-30 13F ARROWHEAD PHARMACEUTICALS COMMON STOCK 04280A100 1,000 0 0.00 7 40.00 0.0000
2016-08-10 2016-06-30 13F ARROWHEAD PHARMACEUTICALS COMMON STOCK 04280A100 1,000 1,000 5 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.